Investors

Webcast ImageWebcast
EDELWEISS Phase 2b clinical trial results of linzagolix (OBE2109) for the treatment of endometriosis related pain (Replay)
18 Jun 2018 at 8:00 a.m. ET
EDELWEISS Phase 2b clinical trial results of linzagolix (OBE2109) for the treatment of endometriosis related pain
Monday, June 18, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.